ELTPOTCPharmaceutical PreparationsFiscal year ends March 31

ELITE PHARMACEUTICALS INC /NV/

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.25−0.00 (-1.37%)

Close on Oct 19, 2026

Market cap: $283.02M
P/E (TTM): 5.0
Dividend yield: –

ELITE PHARMACEUTICALS INC /NV/ balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31	FY 2019 2019-03-31	FY 2018 2018-03-31	FY 2017 2017-03-31	FY 2016 2016-03-31	FY 2015 2015-03-31	FY 2014 2014-03-31	FY 2013 2013-03-31	FY 2012 2012-03-31	FY 2011 2011-03-31	FY 2010 2010-03-31
Cash & Equivalents	30	11	7.11	7.83	8.54	3.19	1.54	2.68	7.57	11	12	7.46	6.94	0.37	0.67	1.83	0.58
Cash & Short-Term Investments	30	11	7.11	7.83	8.54	3.19	1.54	2.68	7.57	11	12	7.46	6.94	0.37	0.67	1.83	0.58
Receivables	60	29	19	3.09	3.06	3.50	4.11	1.32	0.68	0.93	1.53	1.45	0.73	0.67	0.40	0.57	–
Inventory	21	16	13	9.55	6.74	5.01	4.14	4.52	4.90	6.42	3.29	3.03	1.93	1.36	0.30	0.62	–
Prepaid Expenses & Other	1.33	0.98	0.52	1.03	0.53	0.49	0.87	0.74	0.95	0.47	0.38	0.39	0.32	0.15	0.13	0.13	–
Total Current Assets	112	58	40	22	19	12	10	8.86	14	18	17	12	9.92	2.54	1.50	3.15	–
Property, Plant & Equipment	10	10	10	10	5.95	6.65	7.23	8.44	8.99	9.04	8.11	6.40	4.20	4.03	4.28	4.12	–
Gross Property, Plant & Equipment	28	27	26	25	19	19	18	18	17	16	15	12	9.71	9.10	8.94	–	–
Accumulated Depreciation	-18	-17	-16	-15	-13	-12	-11	-9.65	-8.41	-7.43	-6.73	-6.07	-5.51	-5.07	-4.66	-4.19	–
Operating Lease Right-of-Use Assets	1.53	2.00	2.36	0.01	1.03	0.21	0.36	0.55	–	–	–	–	–	–	–	–	–
Intangible Assets	4.79	5.64	6.34	6.34	6.63	6.63	6.63	6.63	7.71	6.42	6.41	6.38	6.35	0.69	0.64	0.60	–
Deferred Tax Assets	7.82	18	22	2.17	2.17	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	–	–	–	–	–	–	0.48	0.47	0.47	0.44	0.44	0.81	3.84	–	–	–	–
Total Assets	138	96	84	41	35	26	25	24	31	34	32	26	24	11	10	12	–
Accounts Payable	6.05	2.96	2.71	2.45	1.43	0.93	1.58	1.38	1.66	1.05	1.80	3.38	2.21	1.33	1.07	0.94	–
Accrued Expenses	10	3.80	5.30	5.05	4.69	4.27	4.82	3.71	1.79	0.79	0.56	0.61	–	–	–	–	–
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	0.03	0	–	–	–	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	–	–	–	–	–	0.31	0.27	0.09	–	–	–	–
Current Debt	–	–	–	–	–	–	–	–	–	–	0.34	0.27	0.09	–	–	–	–
Current Portion of Leases	0.54	0.47	0.41	0.01	0.20	0.19	0.21	0.38	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	0.59	0.34	0.49	0.41	0.41	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	0.01	0.01	0.01	0.01	0.01	0.18	1.01	1.01	1.01	1.01	0.01	0.01	0.01	0.01	0.01	–
Total Current Liabilities	17	12	13	7.83	6.69	5.81	8.64	6.91	5.11	3.34	4.64	5.07	6.16	5.36	4.55	4.67	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	0.02	0	0	0.08	–
Long-Term Leases	1.02	1.55	1.96	–	0.84	0.04	0.17	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	1.55	2.02	2.37	0.00	1.04	0.23	0.38	0.60	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	0.04	0.04	0.04	0.05	0.04	0.03	0.05	0.63	0.13	0.09	0.09	0.08	–
Total Liabilities	39	43	26	12	9.93	10	14	13	12	8.65	21	26	106	20	25	30	–
Total Debt	–	–	–	–	–	–	–	–	–	–	0.34	0.27	0.11	0	0	0.08	–
Preferred Stock	–	–	–	14	14	14	14	–	–	–	–	–	–	–	–	–	–
Common Stock	1.08	1.07	1.07	1.01	1.01	1.01	0.84	0.82	0.80	0.93	0.71	0.63	0.56	0.37	0.33	0.18	–
Additional Paid-In Capital	174	173	173	165	165	164	150	149	147	164	109	107	144	120	115	97	–
Retained Earnings	-76	-121	-116	-136	-140	-149	-154	-152	-143	-139	-143	-142	-225	-128	-130	-115	–
Treasury Stock	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31	–
Shareholders' Equity	99	54	58	29	25	16	11	-2.51	4.57	26	-33	-35	-81	-8.67	-15	-18	-11
Total Equity	99	54	58	29	25	16	11	-2.51	4.57	26	-33	-35	-81	-8.67	-15	-18	-11
Total Liabilities & Equity	138	96	84	41	35	26	25	24	31	34	32	26	24	11	10	12	–
Shares Outstanding(shares)	1,077	1,068	1,068	1,014	1,011	1,009	840	825	803	928	711	631	560	374	332	181	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 43.5%
Operating margin: 24.8%
Net margin: 40.2%
Return on equity, FY2026: 58.9%

Financial strength

Current ratio: 3.76
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 127.9%

Valuation

P/E ratio: 5.0
Price to sales: 2.01
Price to book: 2.70
Dividend yield: –